2024-11-06 - Analysis Report
## Johnson & Johnson (JNJ) Stock Analysis Report

**1.  Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational healthcare company that develops and sells a wide range of pharmaceuticals, medical devices, and consumer healthcare products. JNJ's cumulative return of 32.0% is significantly lower than the S&P 500's (VOO) return of 134.06%. The relative divergence of -102.06 indicates that JNJ has underperformed the S&P 500 by a significant margin. The historical data shows that JNJ's performance relative to the S&P 500 has been consistently lower, with the current situation being in the 3.1st percentile of the historical range.

**Alpha and Beta Analysis:**

JNJ's alpha and beta values vary over time. The alpha values suggest that JNJ has outperformed the market in some periods (2015-2017, 2016-2018), but has underperformed in others (2017-2019, 2018-2020, 2019-2021). The beta values indicate that JNJ's stock is generally less volatile than the overall market, but has shown greater correlation with the market in more recent periods (2020-2022, 2021-2023).

**2.  Recent Price Movement:**

As of now, JNJ's closing price is 158.35. The 5-day moving average is 159.44, the 20-day moving average is 161.89, and the 60-day moving average is 162.65. The current price is below all three moving averages, indicating a potential downward trend.

**3.  Technical Indicators:**

JNJ's RSI is 32.47, which suggests that the stock is currently oversold. The PPO is -0.31, indicating a weak bearish trend. The recent 20-day relative divergence change of -1.75 signifies a short-term downtrend. While the current price is not considered a sudden spike or drop, the overall technical indicators point to a potential short-term decline. The expected return for JNJ is 0.0%, suggesting that long-term investment in the stock might not yield significant returns compared to the S&P 500.

**4.  Recent Earnings and Outlook:**

JNJ's most recent earnings release (2024-10-23) showed EPS of 1.12 and revenue of 22.47 B$. The earnings were slightly lower than analysts' expectations of 1.15. The company's revenue has remained consistently high, but there are concerns regarding profit margins and growth prospects. The overall trend of the company's earnings suggests stability but lacks significant growth potential.

**5.  Financial Information:**

JNJ's financial data reveals a strong and stable company with robust revenue and profitability. The profit margin consistently hovers around 69%, indicating efficient operations and strong earnings power. The equity and ROE data indicate a solid capital structure and ability to generate returns for shareholders. However, the slight decline in profitability over the past few quarters might signal a potential slowdown in future growth.

**6.  News and Recent Issues:**

Recent news regarding JNJ has focused on its earnings reports, with analysts expressing mixed opinions on the company's future prospects. Some analysts are optimistic about JNJ's ability to navigate the current economic environment and maintain its strong financial position, while others are concerned about the potential for slowed growth and increased competition. 

**Recent Market Outlook for JNJ:**

Analysts have issued mixed recommendations for JNJ, with some suggesting a hold while others recommend buying. The overall consensus seems to be that JNJ is a stable and reliable investment, but may not offer significant growth potential.

**Analyst Opinions and Performance Highlights:**

FINBOLD reports that analysts are optimistic about JNJ's long-term performance, particularly in the pharmaceutical and medical device sectors. They believe that JNJ's focus on research and development, coupled with its diverse product portfolio, will allow the company to continue to perform well in the future.

**7.  Comprehensive Analysis:**

JNJ is a financially sound and stable company with a strong track record of performance. However, its current share price performance is significantly below the S&P 500. The company's earnings have remained consistent, but growth is showing signs of slowdown. Technical indicators suggest a potential short-term downturn, while analysts offer mixed opinions on its future performance. Investors looking for significant capital appreciation may want to consider other investment options. However, JNJ remains a viable option for investors seeking a stable and reliable dividend-paying stock with long-term potential.

**8.  Final Recommendations:**

- JNJ is a large-cap, stable and reliable company with a long history of consistent financial performance.
- The current performance is below the market, but the stock is undervalued considering the company's fundamentals.
- Investors should consider JNJ for long-term investment, but should not expect high returns.
- Monitor the company's financial performance and news for potential changes in the future.
- Conduct thorough research and consult with a financial advisor before making any investment decisions.
